

Sphingosylphosphorylcholine acts in an anti-inflammatory manner in renal mesangial cells by reducing interleukin-1 β -induced prostaglandin E₂ formation

Cuiyan Xin,^{1,*} Shuyu Ren,^{1,*} Wolfgang Eberhardt,[†] Josef Pfeilschifter,[†] and Andrea Huwiler^{2,*},[†]

Institute of Pharmacology,* University of Bern, CH-3010 Bern, Switzerland; Pharmazentrum Frankfurt/Zentrum für Arzneimittel Forschung Entwicklung und Sicherheit,[†] Klinikum der Johann Wolfgang Goethe-Universität, D-60590 Frankfurt am Main, Germany

Abstract Sphingosylphosphorylcholine (SPC) is a bioactive lipid that binds to G protein-coupled-receptors and activates various signaling cascades. Here, we show that in renal mesangial cells, SPC not only activates various protein kinase cascades but also activates Smad proteins, which are classical members of the transforming growth factor- β (TGF β) signaling pathway. Consequently, SPC is able to mimic TGF β -mediated cell responses, such as an anti-inflammatory and a profibrotic response. Interleukin-1 β -stimulated prostaglandin E₂ formation is dose-dependently suppressed by SPC, which is paralleled by reduced secretory phospholipase A₂ (sPLA₂) protein expression and activity. This effect is due to a reduction of sPLA₂ mRNA expression caused by inhibited sPLA₂ promoter activity. Furthermore, SPC upregulates the profibrotic connective tissue growth factor (CTGF) protein and mRNA expression. Blocking TGF β signaling by a TGF β receptor kinase inhibitor causes an inhibition of SPC-stimulated Smad activation and reverses both the negative effect of SPC on sPLA₂ expression and the positive effect on CTGF expression. **In summary, our data show that SPC, by mimicking TGF β , leads to a suppression of proinflammatory mediator production and stimulates a profibrotic cell response that is often the end point of an anti-inflammatory reaction. Thus, targeting SPC receptors may represent a novel therapeutic strategy to cope with inflammatory diseases.**—Xin, C., S. Ren, W. Eberhardt, J. Pfeilschifter, and A. Huwiler. **Sphingosylphosphorylcholine acts in an anti-inflammatory manner in renal mesangial cells by reducing interleukin-1 β -induced prostaglandin E₂ formation.** *J. Lipid Res.* 2007. 48: 1985–1996.

Supplementary key words transforming growth factor- β ₂ • Smad • secretory phospholipase A₂ • connective tissue growth factor

Sphingosylphosphorylcholine (SPC) is a lysosphingolipid showing structural similarities to sphingosine 1-phosphate (S1P) and lysophosphatidylcholine (LPC). Similar to S1P and LPC, SPC acts by binding to and activating cell surface

receptors and thereby triggers various cell responses, such as vasoconstriction or vasodilation, angiogenesis, stress fiber formation, and cytoskeletal rearrangements (1, 2).

High-affinity SPC receptors have been reported, including G protein-coupled receptor 4 (GPR4) (3), GPR12 (4), GPR68 (OGR1) (5), and G2A (6), whereas low-affinity SPC binding receptors include the S1P receptors (reviewed in Refs. 1, 2). However, the identity of these receptors as high-affinity SPC receptors remains controversial and unclear, as several of these first reports were retracted. Recently, G2A and GPR68/OGR1 were shown to be activated by decreasing the pH rather than by SPC (7). Furthermore, GPR12 was reported as unresponsive to SPC (8), and SPC binding to GPR4 could not be confirmed by Bektas et al. (9). Considering these latter negative reports, it is clear that the high-affinity SPC receptors responsible for SPC-triggered signal transduction and SPC-induced cell responses still need to be identified.

Physiologically, SPC and S1P have both been shown to exert renal effects in vivo. Intravenous bolus injection of S1P, but not SPC, dose-dependently reduced renal blood flow, whereas both sphingolipids exerted a similar effect on the tubular system to enhance diuresis and natriuresis (10). The reduced renal blood flow by S1P is attributable to a contraction of intrarenal resistance vessels (11, 12), whereas the diuretic effects of S1P and SPC are probably based on an alteration of transport processes in the distal part of the nephron (11, 12).

Abbreviations: COX-2, cyclooxygenase-2; CTGF, connective tissue growth factor; GPR4, G protein-coupled receptor 4; IL-1 β , interleukin-1 β ; LPC, lysophosphatidylcholine; MAPK, mitogen-activated protein kinase; PGE₂, prostaglandin E₂; PKB, protein kinase B; PLA₂, phospholipase A₂; S1P, sphingosine 1-phosphate; SBE, Smad binding element; siRNA, small interfering RNA; SM, sphingomyelin; SPC, sphingosylphosphorylcholine; sPLA₂, secretory phospholipase A₂; TGF β , transforming growth factor- β ; TIE, transforming growth factor- β inhibitory element; TKI, transforming growth factor- β receptor type I kinase inhibitor.

¹C. Xin and S. Ren contributed equally to this work.

²To whom correspondence should be addressed.

e-mail: huwiler@pki.unibe.ch

Manuscript received 12 February 2007 and in revised form 19 June 2007.

Published, JLR Papers in Press, June 25, 2007.

DOI 10.1194/jlr.M700077-JLR200

Copyright © 2007 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at <http://www.jlr.org>

One of the early effects triggered by SPC and SIP in various cell culture systems is an intracellular Ca^{2+} mobilization. In mesangial cells, it was previously shown that SPC- and SIP-stimulated Ca^{2+} mobilization occur via different mechanisms (13). Whereas SIP acted exclusively through PLC activation and inositol 1,4,5-trisphosphate generation to mobilize Ca^{2+} from intracellular stores, SPC additionally also stimulated Ca^{2+} influx (13). Again, this highlights the fact that SPC and SIP trigger divergent signaling cascades.

Renal mesangial cells are involved in the regulation of the glomerular filtration rate as well as in the preservation of the structural integrity of the glomerulus. Furthermore, they play a central role in most pathological processes of the renal glomerulus (14–16). Several proinflammatory functions of mesangial cells have been established, including: *i*) increased extracellular matrix production, *ii*) increased inflammatory mediator production, and *iii*) increased mesangial cell proliferation, which are all hallmarks of many forms of glomerulonephritis (14, 15). However, the detailed mechanisms underlying these cell responses are still not completely understood. A particularly important factor in the mechanism of matrix accumulation is transforming growth factor- β (TGF β), whose production is highly induced in many fibrotic diseases, including atherosclerosis and fibrosis of the kidney, liver, and lung (17–19).

In this study, we show that SPC is able to act on mesangial cells to rapidly activate various signaling cascades, including the mitogen- and stress-activated protein kinases, protein kinase B (PKB), and the Smad proteins, which are members of the TGF β signaling device. This cross-activation of the TGF β /Smad signaling cascade leads on the one hand to an inhibition of interleukin-1 β (IL-1 β)-induced group IIA secretory phospholipase A₂ (sPLA₂) protein expression, mRNA expression, and promoter activity and on the other hand to an activation of gene transcription of the profibrotic connective tissue growth factor (CTGF).

MATERIALS AND METHODS

Chemicals

SIP and SPC were obtained from Biotrend (Köln, Germany); IL-1 β was obtained from Cell Concept (Umkirch, Germany); TGF β ₂ was from R&D Systems (Wiesbaden, Germany); and the TGF β receptor type I kinase inhibitor was from Merck Biosciences (Schwalbach, Germany). The Rediprime II random prime labeling system, Nick columns, prostaglandin E₂ (PGE₂) ELISA, [α -³²P]dCTP, hyperfilm MP, and horseradish-coupled secondary antibodies were from Amersham Pharmacia Biotech (Freiburg, Germany). All phospho-specific antibodies were from Cell Signaling (Frankfurt am Main, Germany); monoclonal rat sPLA₂ antibody was kindly provided by Henk van den Bosch (20). The total Smad-3 (FL-425) antibody (sc-8332), Smad-4 (B-8) antibody (sc-7966), CTGF (L-20) antibody (sc-14939), and cyclooxygenase-2 (COX-2; M-19) antibody (sc-1747) were from Santa Cruz Biotechnology (Heidelberg, Germany); Trizol and all cell culture nutrients were from Gibco Invitrogen (Karlsruhe, Germany).

Cell culture

Rat renal mesangial cells were cultivated and characterized as described previously (21). Passages 9–22 were used for the experiments in this study.

Cell stimulation and Western blot analysis

Confluent mesangial cells in 60 mm diameter dishes were rendered quiescent by incubation for 20 h in DMEM containing 0.1 mg/ml fatty acid-free BSA in the same medium as indicated. Thereafter, the medium was withdrawn and the cells were washed once with ice-cold PBS solution. Cells were scraped into ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 2 mM EGTA, 40 mM β -glycerophosphate, 50 mM sodium fluoride, 10 μ g/ml leupeptin, 10 μ g/ml aprotinin, 1 μ M pepstatin A, and 1 mM PMSF) and homogenized by 10 passes through a 26 gauge needle fitted to a 1 ml syringe. Samples were centrifuged for 10 min at 16,000 *g*, and the supernatant was taken for protein determination. Cell extracts containing 50 μ g of protein were separated by SDS-PAGE and transferred to a nitrocellulose membrane followed by immunostaining, as described previously in detail (22). Antibodies were diluted in blocking buffer as indicated in the figure legends. Bands were detected by the ECL method as recommended by the manufacturer.

Nuclear fractionation of proteins

Stimulated cells were scraped into ice-cold buffer containing 0.5 mM EDTA in PBS and centrifuged for 1 min at 2,300 *g* at 4°C. The pellet was resuspended in buffer containing 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 10 μ g/ml leupeptin, 1 μ M pepstatin A, 10 mM DTT, and 2 mM PMSF and incubated for 15 min at 4°C. After adding 10% (v/v) Nonidet P40, the cell lysate was centrifuged for 1 min at 16,000 *g*. The pellet was further processed by adding buffer containing 20 mM HEPES, pH 7.9, 25% (v/v) glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 10 μ g/ml leupeptin, 1 μ M pepstatin A, 10 mM DTT, and 2 mM PMSF, resuspended by vigorous vortexing for 20 min at 4°C, and centrifuged for 20 min at 16,000 rpm. The supernatant contained nuclear protein and was taken for protein determination.

sPLA₂ secretion and immunostaining

Equal volumes of supernatants derived from the same number of cells were taken for protein precipitation using 10% (w/v) trichloroacetic acid. Precipitated proteins were separated by SDS-PAGE (13% acrylamide gel), transferred to nitrocellulose membranes, and immunostained using a monoclonal antibody against rat group IIA sPLA₂ at a dilution of 1:60, as described previously (20).

sPLA₂ activity assay

Equal volumes of supernatants were taken for an *in vitro* assay using [¹⁴C]oleic acid-labeled *Escherichia coli* as a substrate (23) in a total volume of 0.2 ml including 20 mM Tris-HCl, pH 8.5, and 10 mM CaCl₂. Samples were incubated for 60 min at 37°C and stopped by the addition of 2.5 ml of Dole reagent [isopropyl alcohol-heptane-2 N H₂SO₄ (40:10:1)]. Liberated ¹⁴C-labeled fatty acids were extracted by adding 1.5 ml of heptane and 1 ml of water followed by vigorous vortexing. The heptane phase was loaded onto a silica gel column, and ¹⁴C-labeled free fatty acids were eluted with diethylether and counted in a β -counter.

PGE₂ determination

Equal volumes of supernatants were subjected to a PGE₂ ELISA according to the manufacturer's instructions.

Northern blot analysis

Total RNA was isolated using guanidinium isothiocyanate solution. Twenty micrograms of RNA was separated by electrophoresis on a 1% agarose-formaldehyde gel. RNA was transferred to a nylon membrane and cross-linked by ultraviolet light. Blots were hybridized with a 416 bp RT-PCR product of rat IIA sPLA₂ (forward primer, GGT CCT CCT GTT GCT AGC AG; reverse primer, CTT TGC AAA ACT TGT TGG GG). The probe was labeled with [α -³²P]dCTP using the Multiprime DNA Labeling System (Amersham Pharmacia Biotech). Hybridization was carried out at 42°C for 20 h, and the washed membranes were exposed and analyzed on an Imaging system (Fuji). To correct for variations in RNA amounts, blots were finally rehybridized with a ³²P-labeled GAPDH cDNA probe.

Determination of nitric oxide formation

Quiescent mesangial cells on 24-well plates were stimulated as indicated, and the supernatant was taken for nitrite determination by mixing 50 μ l of the supernatant with 37.5 μ l of Griess reagent. Absorbance at 450 nm was measured in a 96-well spectrophotometer (Tecan). For quantification, a standard curve in the range of 1–100 μ M sodium nitrite was used.

Small interfering RNA transfections

Gene silencing was performed using sequence-specific small interfering RNA (siRNA) reagents: rat Smad4 (AAUACACCGACAA-GCAAUGACdTdT and GUCAUUGCUUGUCGGUGUAUdTdT) and rat TGF β RII (AAAGUCGGUUAACAGCGAUCUdTdT and AGAUCGCUGUUAACCGACUUdTdT). Mesangial cells were transfected at 30–50% confluence with 200 nM of the 21 nucleotide duplexes using Oligofectamine, as recommended by the manufacturer (Dharmacon Research, Inc., Boulder, CO). After 48–72 h, cells were stimulated as indicated in the figure legends. The silencing efficiency was verified by Western blot analyses using specific antibodies.

sPLA₂ promoter studies

A 2.67 kb promoter fragment of rat IIA sPLA₂ was cloned from rat genomic DNA by PCR using the following primers: forward, GCG CCG ACG CGT GAA AAT CCC TGA CTT GAT TC; reverse, GCG CCG CTC GAG GTT TTT CCT GTA CTC CCA ATG, according to a previous report (24) and fused into the luciferase reporter gene-containing vector pGL3. Mesangial cells were cultured on 12-well plates and transfected with 400 ng of plasmid DNA plus 100 ng of Renilla luciferase DNA per well using the Effectene transfection reagent according to the manufacturer's recommendations. Values for IIA sPLA₂ promoter activity were calculated from the ratio of firefly to Renilla luciferase activities and expressed as relative luciferase units.

Statistical analysis

Statistical analysis was performed using one-way ANOVA followed by Bonferroni's post hoc test for multiple comparisons (GraphPad InStat version 3.00 for Windows NT; GraphPad Software, San Diego, CA).

RESULTS

SPC activates the various mitogen-activated protein kinases and the Smad signaling cascades in renal mesangial cells

Stimulation of quiescent renal mesangial cells with SPC led to a very rapid phosphorylation and thereby activation

of the classical mitogen-activated protein kinases (MAPKs) p42- and p44-MAPK (Fig. 1A). Maximal activation was already seen after 5 min of stimulation, which thereafter declined rapidly. At 60 min, a second increase of p42- and p44-MAPK phosphorylation occurred (Fig. 1A). Because a delayed and sustained phase of MAPK activation has been suggested as a prerequisite for cell proliferation (22, 25), this increase at 60 min may be an indication of the proliferative nature of SPC reported previously by others (26). The stress-activated protein kinases p38-MAPK and stress-activated protein kinase/c-Jun N-terminal kinase as well as PKB/Akt were all phosphorylated with similar kinetics




Fig. 1. Time- and concentration-dependent effects of sphingosylphosphorylcholine (SPC) on the activation of the p42/p44-mitogen-activated protein kinases (MAPKs), p38-MAPK, stress-activated protein kinase/c-Jun N-terminal kinase, and protein kinase B (PKB) cascades in renal mesangial cells. A: Quiescent rat renal mesangial cells were stimulated with either vehicle [control (Co); 5 min] or SPC (3 μ M) for the indicated time periods. B: Cells were stimulated for 5 min with the indicated concentrations of SPC. Thereafter, protein extracts containing equal amounts of proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and subjected to Western blot analysis using specific antibodies against phospho-p42/p44-MAPKs (1:1,000), total p42/p44 (1:1,000), phospho-p38-MAPK (1:1,000), total p38-MAPK (1:1,000), phospho-SAPK/JNK (1:1,000), total p45-SAPK (1:1,000), phospho-Ser⁴⁷³-PKB (1:1,000), and total PKB (1:1,000). Bands were visualized by the ECL method according to the manufacturer's instructions. Data are representative of two to three independent experiments giving similar results.

(Fig. 1A), whereas the total protein levels of these enzymes did not change during the stimulation periods (Fig. 1A). The activation of the MAPKs by SPC also occurred in a dose-dependent manner; it showed a clear increase of phosphorylation after 5 min at 10 nM and reached maximal levels at 10 μ M SPC (Fig. 1B).

Furthermore, we found that the Smad signaling pathway, which is classically activated by TGF β , was also activated in a time-dependent manner by SPC. Notably, the maximal effect of SPC on Smad-1 (Fig. 2A) and Smad-2 (Fig. 2B) phosphorylation was seen at 15–20 min of stimu-

lation, which occurred later compared with the very rapid activation of p42/p44-MAPKs, p38-MAPK, stress-activated protein kinase/N-terminal c-Jun kinase, and PKB. Smad-3 was maximally phosphorylated at 5–10 min (Fig. 2C). Because the total Smad-3 antibody (FL-425) is known to cross-react with Smad-2 and to a lesser extent also with Smad-1, -5, and -8, several bands were seen (Fig. 2C, inset). None of these bands was altered upon stimulation. Moreover, the Smad-1, -2, and -3 phosphorylations at 15 min of stimulation increased in a concentration-dependent manner (Fig. 2D–F). To determine whether the increased phos-




Fig. 2. Time- and concentration-dependent effects of SPC on the activation of Smad proteins in renal mesangial cells. A–C: Quiescent mesangial cells were stimulated with either vehicle [control (Co); 15 min] or SPC (3 μ M) for the indicated time periods. D–F: Cells were stimulated for 15 min with the indicated concentrations of SPC. Thereafter, total cell lysates containing equal amounts of proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and subjected to Western blot analysis using phospho-specific and total antibodies against Smad-1 (inset in A), Smad-2 (inset in B), or Smad-3 (inset in C) (all at dilutions of 1:1,000). Bands were visualized by the ECL method according to the manufacturer's instructions, and bands corresponding to the Smad proteins were densitometrically evaluated. Results are expressed as percentages of maximal SPC stimulation and are means \pm SD ($n = 2$ –3). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, considered statistically significant compared with vehicle-stimulated control values.




Fig. 2. Continued.

phorylation of Smads is associated with an activation of the cascade, translocation of the coregulatory Smad-4 to the nucleus was investigated upon fractionation of cell lysates. As seen in **Fig. 3**, unstimulated cells contained only a minor amount of Smad-4 in the nucleus. However, upon $\text{TGF}\beta_2$ stimulation, an accumulation of Smad-4 in the nucleus was seen that remained for up to 3 h of stimulation. In addition, SPC-stimulated cells also showed increased staining of Smad-4 in the nucleus, although this

effect was more transient and less pronounced than that seen for $\text{TGF}\beta_2$. This cross-activation of the $\text{TGF}\beta$ /Smad cascade by SPC critically depended on the $\text{TGF}\beta$ receptor complex, because a recently developed $\text{TGF}\beta$ receptor type I kinase inhibitor (27) dose-dependently reduced SPC-triggered Smad phosphorylation (**Fig. 4A**). In addition, the Smad-1 phosphorylation was also abolished when depleting the $\text{TGF}\beta$ receptor type II by siRNA transfection of the cells (**Fig. 4B**).




Fig. 3. Effects of transforming growth factor- β ($\text{TGF}\beta_2$) and SPC on Smad-4 translocation to the nucleus in renal mesangial cells. Quiescent cells were stimulated with vehicle [control (Co); 15 min], $\text{TGF}\beta_2$ (10 ng/ml; upper inset), or SPC (3 μM ; lower inset) for the indicated time periods. Thereafter, nuclear extracts were prepared as described in Materials and Methods, and proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and subjected to Western blot analysis using a specific antibody against Smad-4 (1:1,000). Bands were visualized by the ECL method according to the manufacturer's instructions and densitometrically evaluated. Results are expressed as percentages of maximal $\text{TGF}\beta$ stimulation and are means \pm SD of two independent experiments.

SPC suppresses IL-1 β -induced inflammatory mediator production

In a next step, we investigated whether SPC was able to mimic $\text{TGF}\beta$ -mediated cell responses. $\text{TGF}\beta$ is well known to exert various biological effects, including an immunosuppressive effect, an anti-inflammatory effect, and a profibrotic effect, depending on the cell system. Previously, it was shown that in mesangial cells, $\text{TGF}\beta$ suppresses important proinflammatory enzyme systems such as the sPLA₂ or the inducible nitric oxide synthase. Stimulation of mesangial cells for 24 h with IL-1 β led to a large increase of PGE₂ formation (Fig. 5A). In the presence of SPC, IL-1 β -induced PGE₂ generation was partially suppressed. A significant effect (50% inhibition) was already seen at very low

concentrations of 1 nM SPC, which was not further reduced by increasing the concentration to 10 μM . IL-1 β -stimulated nitric oxide release was also reduced by SPC, but with a completely different potency compared with PGE₂ (Fig. 5B), which may suggest a different mode of action of SPC in the regulation of nitric oxide release.

To further elucidate the effect of SPC on PGE₂ formation, the expression of the IIA sPLA₂ was studied. Protein expression of IIA sPLA₂ in the supernatant, which was highly induced by IL-1 β , was dose-dependently blocked by SPC (Fig. 6A). A similar reducing effect was also seen for the mRNA expression of IIA sPLA₂ (Fig. 6B), whereas the housekeeping enzyme GAPDH was not affected by either IL-1 β or SPC (Fig. 6B).

Subsequently, the mechanism by which SPC can block sPLA₂ mRNA expression was investigated. mRNA steady-state levels may be reduced by two possible mechanisms: either by a reduced promoter activity or by increased mRNA degradation. To this end, we performed promoter studies. A 2.67 kb fragment of the rat sPLA₂ promoter was cloned and fused to a luciferase-containing vector (24). Transfection of mesangial cells with this sPLA₂ promoter fragment followed by stimulation for 24 h with IL-1 β led to increased promoter activity (Fig. 7), confirming previous reports (24, 28). The cytokine-induced promoter activation was significantly, although only partially, reduced in the presence of SPC, resembling the partial effect of SPC on sPLA₂ mRNA expression seen in Fig. 6B. $\text{TGF}\beta$ was a more potent suppressor and completely abolished sPLA₂ promoter activity (Fig. 7). Moreover, the effect of SPC on sPLA₂ mRNA degradation was measured and was not affected by SPC (data not shown).

Furthermore, we determined whether this reducing effect of SPC on IIA sPLA₂ expression also involved the $\text{TGF}\beta$ /Smad cascade. To this end, cells were pretreated with the specific kinase inhibitor of the transforming growth factor- β receptor type I kinase (TKI). As seen in Fig. 8A, the suppressing effect of SPC on IL-1 β -stimulated sPLA₂ protein expression was reversed in the presence of TKI. Similarly, SPC-suppressed IIA sPLA₂ promoter activity was also reversed by TKI (Fig. 8B).




Fig. 4. Effects of $\text{TGF}\beta$ receptor types I and II (RI and RII) blockade on SPC-induced Smad phosphorylation. Quiescent mesangial cells were pretreated with vehicle [–; control (Co)] or the $\text{TGF}\beta$ RI inhibitor (10 μM ; A) or $\text{TGF}\beta$ RII small interfering RNA (siRNA) (B) before SPC stimulation (3 μM) as described in Materials and Methods. Thereafter, cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membranes, and subjected to Western blot analysis using specific antibodies against phospho-Smad-1 (1:1,000) and total Smad-1 (1:1,000). Bands were visualized by the ECL method according to the manufacturer's instructions. Data are representative of three independent experiments giving similar results. TKI, transforming growth factor- β receptor type I kinase inhibitor.




Fig. 5. Effects of SPC on interleukin-1 β (IL-1 β)-induced prostaglandin E₂ (PGE₂) and nitric oxide formation in mesangial cells. Quiescent mesangial cells were stimulated for 24 h with either vehicle (-) or IL-1 β (1 nM; +) in the absence or presence of the indicated concentrations of SPC. Thereafter, supernatants were taken for the determination of PGE₂ formation (A) or nitrite formation (B) as described in Materials and Methods. Data are expressed as percentages of control and are means \pm SD (n = 4). ** $P < 0.01$, *** $P < 0.001$, considered statistically significant compared with IL-1 β -stimulated values.

Because TGF β not only activates the regulatory Smad proteins but also induces the antagonistic Smad-7 (29), we investigated whether Smad-7 is upregulated by SPC and could account for the suppressive effect on PGE₂ formation. However, at up to 24 h of SPC stimulation, there was no expression of Smad-7 (data not shown).

To determine whether the reducing effect of SPC on cytokine-triggered PGE₂ synthesis also involves changes in COX-2 expression, we investigated the protein expression of COX-2. However, SPC did not significantly affect COX-2 protein expression (data not shown) suggesting that downregulation of the rate-limiting enzyme sPLA₂ is sufficient to reduce PGE₂ synthesis.

SPC-activated transcription of the profibrotic factor CTGF

In a final step, we investigated whether the profibrotic response classically triggered by TGF β is also mimicked by SPC. One well-described profibrotic factor that is highly upregulated by TGF β is the CTGF (30–32). Stimulation of




Fig. 6. Effects of SPC on IL-1 β -induced secretory phospholipase A₂ (sPLA₂) mRNA and protein expression in mesangial cells. Quiescent mesangial cells were stimulated for 24 h with either vehicle (-) or IL-1 β (1 nM; +) in the absence or presence of the indicated concentrations of SPC. Thereafter, supernatants were taken for protein precipitation followed by protein separation by SDS-PAGE, transfer to nitrocellulose, and Western blot analysis using a specific monoclonal antibody against rat IIA sPLA₂ at a dilution of 1:60 (A), or mRNA was extracted from the cell monolayer and subjected to Northern blot analysis using a specific probe for rat IIA sPLA₂ (B, upper panel) or GAPDH (B, lower panel). Bands in A were visualized by the ECL method according to the manufacturer's instructions. Bands in B were analyzed by an imaging system (Fuji). Data are representative of three independent experiments giving similar results.

mesangial cells with SPC caused a time-dependent increase of CTGF protein expression (Fig. 9). Already after 1 h, a clear upregulation was seen compared with vehicle-treated cells (Fig. 9). This, however, was no longer seen




Fig. 7. Effects of SPC and TGF β ₂ on IL-1 β -stimulated rat IIA sPLA₂ promoter activation. Mesangial cells were transfected with empty vector or a 2.67 kb fragment of the rat IIA sPLA₂ promoter plus the plasmid coding for Renilla luciferase. Twenty-four hours after transfection, cells were rendered serum-free and stimulated for 16 h with either vehicle [control (Co)] or IL-1 β (1 nM) in the absence or presence of SPC (3 μ M) or TGF β ₂ (10 ng/ml). The ratio between beetle and Renilla luciferase activities was calculated and is depicted as % of control relative luciferase activity [relative luciferase units (RLU)]. Data are means \pm SD (n = 3). *** $P < 0.001$, considered statistically significant compared with vehicle-stimulated control values; ## $P < 0.01$, ### $P < 0.001$, considered statistically significant compared with IL-1 β -stimulated control values.




Fig. 8. Effects of TGF β receptor inhibition on SPC-mediated inhibition of sPLA₂ protein expression and promoter activation in renal mesangial cells. **A:** Quiescent mesangial cells were stimulated with vehicle (–), IL-1 β (1 nM), IL-1 β + SPC (3 μ M), or IL-1 β + SPC + TKI (10 μ M, pretreated for 20 min). Thereafter, supernatants were taken for protein precipitation followed by protein separation by SDS-PAGE, transfer to nitrocellulose, and Western blot analysis using a specific monoclonal antibody against rat IIA sPLA₂ antibody at a dilution of 1:60. **B:** Cells were transfected with the rat IIA sPLA₂ promoter plus the plasmid coding for Renilla luciferase. Twenty-four hours after transfection, cells were rendered serum-free and stimulated for 16 h with vehicle (–), IL-1 β (1 nM), IL-1 β + SPC (3 μ M), or IL-1 β + SPC + TKI (10 μ M, pretreated for 20 min). The ratio between beetle and Renilla luciferase activities was calculated and is depicted % of control as relative luciferase activity [relative luciferase units (RLU)]. Data are means \pm SD (n = 3). *** P < 0.001, considered statistically significant compared with vehicle-stimulated control values; ## P < 0.01, considered statistically significant compared with IL-1 β -stimulated values; \$\$\$ P < 0.001, considered statistically significant compared with IL-1 β + SPC-stimulated values.

after 24 h, as a result of the high basal levels of CTGF produced in vehicle-treated cells. The stimulating effect of SPC on CTGF at 4 h was significantly blocked in the presence of the TGF β RI kinase inhibitor (**Fig. 10A**). Additionally, depletion of the TGF β RII by siRNA (**Fig. 10B**), or depletion of the downstream Smad-4 by siRNA (**Fig. 10C**), caused a marked, although only partial, reduction of SPC-induced CTGF protein expression.

DISCUSSION

In this study, we show for the first time that SPC displays an anti-inflammatory capacity in renal mesangial cells.




Fig. 9. Effects of SPC on connective tissue growth factor (CTGF) protein expression in renal mesangial cells. Cells were stimulated for the indicated time periods with either vehicle (–) or SPC (3 μ M; +). Thereafter, protein lysates were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis using antibodies against CTGF (upper panel) or GAPDH (lower panel) at dilutions of 1:1,000 each. Bands were visualized by the ECL method according to the manufacturer's instructions. Data are representative of three independent experiments giving similar results.

Evidence is given by the fact that the expression of the IIA sPLA₂, which is considered a proinflammatory enzyme and affects the production of prostaglandins, is suppressed by SPC and consequently leads to a downregulation of PGE₂ synthesis. Mechanistically, this suppression of sPLA₂ mRNA expression is attributable to the activation of the TGF β /Smad signaling cascade and critically involves the TGF β receptor. This conclusion is based on the following findings: *i*) SPC stimulates the phosphorylation and activation of the Smad-1, -2, and -3 proteins (**Fig. 2**), which are blocked by a TGF β receptor type I kinase inhibitor (**Fig. 4A**); *ii*) this TGF β receptor type I kinase inhibitor is also able to reverse the reducing effect of SPC on sPLA₂ protein expression (**Fig. 10A**); and *iii*) depletion of the TGF β receptor type II (**Fig. 10B**) or depletion of the downstream-located Smad-4 (**Fig. 10C**) by siRNA led to a reversal of the SPC effect. However, the activation of the TGF β /Smad pathway by SPC occurs independent of TGF β itself, as there is no increase of active TGF β in the supernatant of SPC-treated cells when measured by ELISA (data not shown). Furthermore, neutralizing antibodies against TGF β did not interfere with the SPC-triggered Smad phosphorylation (data not shown).

The finding that SPC stimulates Smad activation is in good agreement with our previous findings that S1P, and also the S1P mimetic FTY720 phosphate, are able to trigger the phosphorylation and activation of Smad proteins (33, 34). It is well established that S1P and FTY720 phosphate bind to the same receptors (35, 36) (i.e., the S1P receptors), and it has been proposed that there is a physical interaction between one of the S1P receptors, most likely S1P₃, and the TGF β receptor (33). This was shown




Fig. 10. Effects of TGF β receptor inhibition and TGF β RII and Smad-4 depletion by siRNA transfection on SPC-induced CTGF protein expression in mesangial cells. **A:** Cells were stimulated with vehicle or pretreated with the indicated concentrations of TKI before stimulation for 4 h with SPC (3 μ M). **B, C:** Cells were transfected with vehicle, siRNA of TGF β RII (**B**), or siRNA of Smad-4 (**C**) as indicated before stimulation for 4 h with either vehicle (-) or SPC (3 μ M; +). Thereafter, protein lysates were prepared and separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis using antibodies against CTGF (insets, upper panels) or GAPDH (insets, lower panels) at dilutions of 1:1,000. Bands were visualized by the ECL method according to the manufacturer's instructions and were densitometrically evaluated. Results are expressed as percentages of maximal SPC stimulation and are means \pm SD ($n = 4$). *** $P < 0.001$, considered statistically significant compared with vehicle-stimulated control values; ### $P < 0.001$, considered statistically significant compared with vehicle-transfected and SPC-stimulated values; § $P < 0.001$, considered statistically significant compared with vehicle transfected unstimulated values.

using chemical cross-linkers, which resulted in an association of several factors with the TGF β receptor type II upon SIP stimulation of mesangial cells (33). Whether SPC binds to the same receptors as SIP in mesangial cells remains unclear. Several *in vitro* studies showed that SPC can bind with low affinity to the SIP receptors. However, recently, high-affinity SPC receptors, such as ovarian cancer OGR1 (or GPR68), G2A (derived from G2 accumulation), and GRP4, were identified. Interestingly, these putative high-affinity SPC receptors are expressed, at least on the mRNA level, in mesangial cells (data not shown) and may mediate

some of the SPC-triggered effects. In view of the concentration dependence of the activation of the MAPKs and Smad proteins, which is already seen at low nanomolar concentrations of SPC (Figs. 1B, 2B), one may speculate that one of the high-affinity SPC receptors is involved. However, it must be noted that not only SIP- but also SPC-induced vasodilation in precontracted aortae is completely abolished in SIP $_3$ -deficient mice, suggesting the involvement of the SIP $_3$ receptor in the SPC action on the endothelium (37).

There is now more evidence accumulating that G protein-coupled receptors undergo not only homodimerization

but also heterodimerization and oligomerization with other receptor classes, thereby triggering cross-talk between different signaling cascades (38). Also, this consideration makes it tempting to speculate that there is a direct interaction of the putative SPC receptor and the TGF β receptor complex. In this regard, it has been shown that the SIP receptors can cross-activate other growth factor signaling cascades, such as vascular endothelial growth factor, epidermal growth factor, and platelet-derived growth factor receptor signaling (39–42).

The question of how Smad proteins negatively interfere with gene transcription is still largely unanswered. Although positive Smad binding elements (SBEs) in promoter regions of certain genes, mainly fibrosis-related genes such as CTGF (30–32), tissue inhibitor of metalloproteinases-1 (43), and plasminogen activator inhibitors (44, 45), are well reported, negative SBEs are seldom described. Ogawa et al. (46) first reported the existence of such a negative SBE-like sequence, denoted as transforming growth factor- β inhibitory element (TIE), in the human matrix metalloproteinase-9 promoter, although depletion and mutation studies revealed that this TIE is not involved in the TGF β -mediated suppressive effect on matrix metalloproteinase-9 promoter activity (46). Recently, a novel suppressive SBE was identified within the TIE of the *c-myc* promoter, termed repressive SBE (47), which is different from the previously defined SBE and dictates the TGF β -mediated repression of *c-myc* and subsequent growth arrest in keratinocytes (47, 48).

Alternatively, it has been suggested that Smad proteins exert a negative effect on gene transcription by indirect mechanisms such as interference with NF κ B (46), AP-1 (49), c-Myc (50), NKX2.1 (51), and hepatocyte nuclear factor-3 (51), which prevents the binding of these transcription factors to their respective DNA binding sites.

The contribution of SPC to physiology and pathophysiology is poorly understood. Most consistently, a role of SPC in cardiovascular physiology is proposed based on the Ca²⁺-mobilizing activity of SPC. Thus, in endothelial cells in situ on bovine aortic valves, SPC increases intracellular Ca²⁺ concentration and nitric oxide production and induces endothelium-dependent relaxation (52). In the smooth muscle of pig coronary arteries, SPC induces vessel contraction via Ca²⁺ sensitization (53). The vascular effects of SPC, and similarly of SIP, have gained further interest as a result of their association with HDL, which is a well accepted atheroprotective factor acting through various parallel protective mechanisms (37, 54). In the context of atherogenesis, SPC was also appointed an anti-inflammatory role as a result of its association with HDL, causing a reduction of the inhibitory effect on tumor necrosis factor- α -triggered NF κ B activation, leading to reduced E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 expression (55).

In addition, SPC may have a relevant role in the regulation of the heart. Thus, SPC and SIP were identified as the plasma and serum factors responsible for activating the inwardly rectifying K⁺ channel [I(K)], leading to a negative chronotropic effect (56).

SPC was also shown to be a potent mitogen for various cell types (27), and it was tempting to speculate that SPC could be involved in tumor development. Indeed, it was shown that SPC levels were significantly higher in ascites caused by ovarian cancer than in nonmalignant ascites (57). It was also proposed that SPC facilitates the metastasis of tumor cells by stimulation of a reorganization of intact keratin filaments, resulting in enhanced tumor cell elasticity (58). In contrast, another study proposed a role for SPC in tumor cell differentiation, as shown for human NB4 promyelocytic leukemia cells (59).

Furthermore, patients with atopic dermatitis have increased SPC and reduced ceramide levels in the skin, which correlate with an enhanced activity of a sphingomyelin (SM) deacylase in the skin of these patients (60–63). This suggests that SPC is formed by a phospholipase A₂ (PLA₂)-like enzymatic activity.

In general, little is known about the pathways of SPC generation and degradation. The SPC concentration in human serum was recently determined by mass spectrometry to be 130 \pm 25 nM (56). Whether this is changed under inflammatory or fibrotic disease conditions has not been addressed. SPC formation is theoretically possible: *i*) from SM by the action of a PLA₂-like enzyme such as the SM deacylase (60, 61); *ii*) from sphingosine by phosphocholine transfer; or *iii*) from SIP by choline transfer. The generation of SPC from SM by PLA₂ activity is an intriguing hypothesis and is further stressed by the finding that cells isolated from Niemann-Pick patients, which possess an acid sphingomyelinase deficiency and consequently accumulate SM in the lysosomes, also show an accumulation of SPC (64). However, the mechanism of this phenomenon was not addressed further. In this context, several forms of lysosomal PLA₂ have been purified and characterized (65). Moreover, a lysosomal PLA₂ was recently cloned that possesses 1-*O*-acylceramide synthase activity (66). Whether one of these PLA₂s also possesses selectivity for SM to generate SPC has not been addressed.

No evidence is available at present to show that choline or phosphocholine transfer may play a role in SPC generation. On the other hand, the conversion of SPC to SIP may be catalyzed by a phospholipase D-like activity. Interestingly, autotaxin, a member of the nucleotide pyrophosphatase/phosphodiesterase family possessing lysophospholipase D activity, is able to hydrolyze LPC to form lysophosphatidic acid (67) as well as SPC to form SIP (68). Whether the conversion of SPC to SIP by autotaxin is of physiological or pathophysiological relevance remains unknown. At least autotaxin was shown to be an absolutely critical enzyme for life, as autotaxin-deficient mice are not viable and die at embryonic day E9.5 from profound vascular defects (69).

In summary, our study clearly shows that TGF β and SPC share the same signaling device (i.e., the activation of the Smad signaling cascade), which strongly resembles the overlapping signaling between TGF β and SIP. Furthermore, SPC not only mimics the anti-inflammatory effect of TGF β on mesangial cells to suppress cytokine-induced PGE₂ formation and nitric oxide release but also exerts a

profibrotic effect, as shown by the upregulation of CTGF. In this way, SPC may represent a novel target for therapeutic strategies to cope with chronic inflammatory and fibrotic diseases. ■■

The authors thank Mrs. Grace Gordon for critically reading the manuscript and Mrs. Luise Reinsberg and Simone Hildbrand for technical assistance. This work was supported by the Swiss National Foundation (Grant 3100A0-111806), the German Research Community (Grants FOG784, GRK757/2, PF 361/6-1, and EB 257/2-1), the Wilhelm Sander-Stiftung, the Novartis Foundation, and the European Community (Grant FP6: LSHM-CT-2004-005033).

REFERENCES

- Meyer zu Heringdorf, D., H. M. Himmel, and K. H. Jakobs. 2002. Sphingosylphosphorylcholine—biological functions and mechanisms of action. *Biochim. Biophys. Acta.* **1582**: 178–189.
- Ishii, I., N. Fukushima, X. Ye, and J. Chun. 2004. Lysophospholipid receptors: signaling and biology. *Annu. Rev. Biochem.* **73**: 321–354.
- Zhu, K., L. M. Baudhuin, G. Hong, F. S. Williams, K. L. Cristina, J. H. Kabarowski, O. N. Witte, and Y. Xu. 2001. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. *J. Biol. Chem.* **276**: 41325–41335.
- Hinckley, M., S. Vaccari, K. Horner, R. Chen, and M. Conti. 2005. The G-protein-coupled receptors GPR3 and GPR12 are involved in cAMP signaling and maintenance of meiotic arrest in rodent oocytes. *Dev. Biol.* **287**: 249–261.
- Xu, Y., K. Zhu, G. Hong, W. Wu, L. M. Baudhuin, Y. Xiao, and D. S. Damron. 2000. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. *Nat. Cell Biol.* **2**: 261–267.
- Kabarowski, J. H., K. Zhu, L. O. Le, O. N. Witte, and Y. Xu. 2001. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. *Science.* **293**: 702–705.
- Ludwig, M. G., M. Vanek, D. Guerini, J. A. Gasser, C. E. Jones, U. Junker, H. Hofstetter, R. M. Wolf, and K. Seuwen. 2003. Proton-sensing G-protein-coupled receptors. *Nature.* **425**: 93–98.
- Uhlenbrock, K., H. Gassenhuber, and E. Kostenis. 2002. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. *Cell. Signal.* **14**: 941–953.
- Bektas, M., L. S. Barak, P. S. Jolly, H. Liu, K. R. Lynch, E. Lacana, K. B. Shur, S. Milstien, and S. Spiegel. 2003. The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner. *Biochemistry.* **42**: 12181–12191.
- Czyborra, C., A. Bischoff, and M. C. Michel. 2006. Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. *Naunyn Schmiedeb. Arch. Pharmacol.* **373**: 37–44.
- Bischoff, A., P. Czyborra, C. Fetscher, D. Meyer zu Heringdorf, K. H. Jakobs, and M. C. Michel. 2000. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. *Br. J. Pharmacol.* **130**: 1871–1877.
- Bischoff, A., D. Meyer zu Heringdorf, K. H. Jakobs, and M. C. Michel. 2001. Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats. *Br. J. Pharmacol.* **132**: 1925–1933.
- Chen, P. F., T. Y. Chin, and S. H. Chueh. 1998. Ca²⁺ signaling induced by sphingosylphosphorylcholine and sphingosine 1-phosphate via distinct mechanisms in rat glomerular mesangial cells. *Kidney Int.* **54**: 1470–1483.
- Pfeilschifter, J. 1989. Cross-talk between transmembrane signalling systems: a prerequisite for the delicate regulation of glomerular haemodynamics by mesangial cells. *Eur. J. Clin. Invest.* **19**: 347–361.
- Pfeilschifter, J. 1994. Mesangial cells orchestrate inflammation in the renal glomerulus. *News Physiol. Sci.* **9**: 271–276.
- Kashgarian, M., and R. B. Sterzel. 1992. The pathobiology of the mesangium. *Kidney Int.* **41**: 524–529.
- Leask, A., and D. J. Abraham. 2004. TGF- β signaling and the fibrotic response. *FASEB J.* **18**: 816–827.
- Kitamura, M., and T. S. Suto. 1997. TGF- β and glomerulonephritis: anti-inflammatory versus prosclerotic actions. *Nephrol. Dial. Transplant.* **12**: 669–679.
- Agrotis, A., N. Kalinina, and A. Bobik. 2005. Transforming growth factor- β , cell signaling and cardiovascular disorders. *Curr. Vasc. Pharmacol.* **3**: 55–61.
- Vervoordeldonk, M. J., G. S. van Rossum, R. M. Sanchez, F. W. Neys, and H. van den Bosch. 1997. Half-life of interleukin-1 β -induced group II phospholipase A₂ in rat mesangial cells. *Biochim. Biophys. Acta.* **1355**: 315–322.
- Pfeilschifter, J., A. Kurtz, and C. Bauer. 1984. Activation of phospholipase C and prostaglandin synthesis by arginine vasopressin in cultures. *Biochem. J.* **223**: 855–859.
- Huwiler, A., S. Stabel, D. Fabbro, and J. Pfeilschifter. 1995. Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. *Biochem. J.* **305**: 777–784.
- Märki, F., and R. Franson. 1986. Endogenous suppression of neutral-active and calcium-dependent phospholipase A₂ in human polymorphonuclear leukocytes. *Biochim. Biophys. Acta.* **879**: 149–156.
- Scholz-Pedretti, K., A. Gans, K-F. Beck, J. Pfeilschifter, and M. Kaszkin. 2002. Potentiation of TNF- α -stimulated group IIA phospholipase A₂ expression by peroxisome proliferator-activated receptor α activators in rat mesangial cells. *J. Am. Soc. Nephrol.* **13**: 611–620.
- Kahan, C., K. Seuwen, S. Meloche, and J. Pouyssegur. 1992. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylcyclase inhibition. *J. Biol. Chem.* **267**: 13369–13375.
- Desai, N. N., and S. Spiegel. 1991. Sphingosylphosphorylcholine is a remarkably potent mitogen for a variety of cell lines. *Biochem. Biophys. Res. Commun.* **181**: 361–366.
- Inman, G. J., F. J. Nicolas, J. F. Callahan, J. D. Harling, L. M. Gaster, A. D. Reith, N. J. Laping, and C. S. Hill. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor- β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. *Mol. Pharmacol.* **62**: 65–74.
- Petry, C., A. Huwiler, W. Eberhardt, M. Kaszkin, and J. Pfeilschifter. 2005. Hypoxia increases group IIA phospholipase A(2) expression under inflammatory conditions in rat renal mesangial cells. *J. Am. Soc. Nephrol.* **16**: 2897–2905.
- Massague, J. 1998. TGF-beta signal transduction. *Annu. Rev. Biochem.* **67**: 753–791.
- Igarashi, A., H. Okochi, D. M. Bradham, and G. R. Grotenhorst. 1993. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. *Mol. Biol. Cell.* **4**: 637–645.
- Riser, B. L., M. Denichilo, P. Cortes, C. Baker, J. M. Grondin, J. Lee, and R. G. Narins. 2000. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. *J. Am. Soc. Nephrol.* **11**: 25–38.
- Leask, A., and D. J. Abraham. 2003. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. *Biochem. Cell Biol.* **81**: 355–363.
- Xin, C., S. Ren, B. Kleuser, S. Shabahang, W. Eberhardt, H. Radeke, M. Schäfer-Korting, J. Pfeilschifter, and A. Huwiler. 2004. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor- β -induced cell responses. *J. Biol. Chem.* **279**: 35255–35262.
- Xin, C., S. Ren, W. Eberhardt, J. Pfeilschifter, and A. Huwiler. 2006. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. *Br. J. Pharmacol.* **147**: 164–174.
- Brinkmann, V., M. D. Davies, C. E. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. *J. Biol. Chem.* **277**: 21453–21457.
- Mandala, S., R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G. J. Shei, D. Card, C. Keohane, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. *Science.* **296**: 346–349.
- Nofer, J. R., M. van der Giet, M. Tolle, I. Wolinska, K. von Wnuck Lipinski, H. A. Baba, U. J. Tietge, A. Godecke, I. Ishii, B. Kleuser, et al. 2004. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. *J. Clin. Invest.* **113**: 569–581.

38. Devi, D. A. 2001. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. *Trends Pharmacol.* **22**: 532–537.
39. Kim, J. H., J. H. Kim, W. K. Song, J. H. Kim, and J. S. Chun. 2000. Sphingosine 1-phosphate activates Erk-1/-2 by transactivating epidermal growth factor receptor in rat-2 cells. *IUBMB Life.* **50**: 119–124.
40. Endo, A., K. Nagashima, H. Kurose, S. Mochizuki, M. Matsuda, and N. Mochizuki. 2002. Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII. *J. Biol. Chem.* **277**: 23747–23754.
41. Tanimoto, T., Z. G. Jin, and B. C. Berk. 2002. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). *J. Biol. Chem.* **277**: 42997–43001.
42. Rani, C. S., F. Wang, E. Fuior, A. Berger, J. Wu, T. W. Sturgill, D. Beitner-Johnson, D. LeRoith, L. Varticovski, and S. Spiegel. 1997. Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling. *J. Biol. Chem.* **272**: 10777–10783.
43. Marti, H. P., L. Lee, M. Kashgarian, and D. H. Lovett. 1994. Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. *Am. J. Pathol.* **144**: 82–94.
44. Akool, el-S., A. Doller, R. Müller, P. Gutwein, C. Xin, A. Huwiler, J. Pfeilschifter, and W. Eberhardt. 2005. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor β -Smad signaling pathway. *J. Biol. Chem.* **280**: 39403–39416.
45. Gerwin, B. I., J. Keski-Oja, M. Seddon, J. F. Lechner, and C. C. Harris. 1990. TGF- β 1 modulation of urokinase and PAI-1 expression in human bronchial epithelial cells. *Am. J. Physiol.* **259**: L262–L269.
46. Ogawa, K., F. Chen, C. Kuang, and Y. Chen. 2004. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. *Biochem. J.* **381**: 413–422.
47. Yagi, K., M. Furuhashi, H. Aoki, D. Goto, H. Kuwano, K. Sugamura, K. Miyazono, and M. Kato. 2002. c-myc is a downstream target of the Smad pathway. *J. Biol. Chem.* **277**: 854–861.
48. Frederick, J. P., N. T. Liberati, D. S. Waddell, Y. Shi, and X. F. Wang. 2004. Transforming growth factor β -mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. *Mol. Cell. Biol.* **24**: 2546–2559.
49. Hallatschek, W., G. Fiedler, C. J. Kirschning, F. Creutzburg, N. Lamping, A. Nussler, and R. R. Schumann. 2004. Inhibition of hepatic transcriptional induction of lipopolysaccharide-binding protein by transforming-growth-factor β 1. *Eur. J. Immunol.* **34**: 1441–1450.
50. Li, H., D. Xu, J. Li, M. C. Berndt, and J. P. Liu. 2006. Transforming growth factor β suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. *J. Biol. Chem.* **281**: 25588–25600.
51. Li, C., N. L. Zhu, R. C. Tan, P. L. Ballard, R. Derynck, and P. Minoo. 2002. Transforming growth factor- β inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2.1 and HNF-3 transcription factors. *J. Biol. Chem.* **277**: 38399–38408.
52. Mogami, K., Y. Mizukami, N. Todoroki-Ikeda, M. Ohmura, K. Yoshida, S. Miwa, M. Matsuzaki, M. Matuda, and S. Kobayashi. 1999. Sphingosylphosphorylcholine induces cytosolic Ca(2+) elevation in endothelial cells in situ and causes endothelium-dependent relaxation through nitric oxide production in bovine coronary artery. *FEBS Lett.* **457**: 375–380.
53. Todoroki-Ikeda, N., Y. Mizukami, K. Mogami, T. Kusuda, K. Yamamoto, T. Miyake, M. Sato, S. Suzuki, H. Yamagata, Y. Hokazono, et al. 2000. Sphingosylphosphorylcholine induces Ca(2+)-sensitization of vascular smooth muscle contraction: possible involvement of rho-kinase. *FEBS Lett.* **482**: 85–90.
54. Nofer, J. R., and G. Assmann. 2005. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. *Trends Cardiovasc. Med.* **15**: 265–271.
55. Schmidt, A., S. Geigenmuller, W. Volker, and E. Buddecke. 2006. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt \rightarrow NF- κ B signalling pathways in human vascular endothelial cells. *Basic Res. Cardiol.* **101**: 109–116.
56. Liliom, K., G. Sun, M. Bunemann, T. Virag, N. Nusser, D. L. Baker, D. A. Wang, M. J. Fabian, B. Brandts, K. Bender, et al. 2001. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. *Biochem. J.* **355**: 189–197.
57. Seijo, L., T. E. Merchant, L. T. van der Ven, B. D. Minsky, and T. Glonek. 1994. Meningioma phospholipid profiles measured by 31 P nuclear magnetic resonance spectroscopy. *Lipids.* **29**: 359–364.
58. Beil, M., A. Micoulet, G. von Wichert, S. Paschke, P. Walther, M. B. Omary, P. P. van Veldhoven, U. Gern, E. Wolff-Hieber, J. Eggermann, et al. 2003. Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells. *Nat. Cell Biol.* **5**: 803–811.
59. Kleger, A., T. Busch, S. Liebau, K. Prella, S. Paschke, M. Beil, A. Rolletschek, A. Wobus, E. Wolf, G. Adler, et al. 2007. The bioactive lipid sphingosylphosphorylcholine induces differentiation of mouse embryonic stem cells and human promyelocytic leukaemia cells. *Cell. Signal.* **19**: 367–377.
60. Hara, J., K. Higuchi, R. Okamoto, M. Kawashima, and G. Imokawa. 2000. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. *J. Invest. Dermatol.* **115**: 406–413.
61. Higuchi, K., J. Hara, R. Okamoto, M. Kawashima, and G. Imokawa. 2000. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. *Biochem. J.* **350**: 747–756.
62. Murata, Y., J. Ogata, Y. Higaki, M. Kawashima, Y. Yada, K. Higuchi, T. Tsuchiya, S. Kawainami, and G. Imokawa. 1996. Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency? *J. Invest. Dermatol.* **106**: 1242–1249.
63. Imokawa, G., Y. Takagi, K. Higuchi, H. Kondo, and Y. Yada. 1999. Sphingosylphosphorylcholine is a potent inducer of intercellular adhesion molecule-1 expression in human keratinocytes. *J. Invest. Dermatol.* **112**: 91–96.
64. Berger, A., D. Rosenthal, and S. Spiegel. 1995. Sphingosylphosphocholine, a signaling molecule which accumulates in Niemann-Pick disease type A, stimulates DNA-binding activity of the transcription activator protein AP-1. *Proc. Natl. Acad. Sci. USA.* **92**: 5885–5889.
65. Hostetler, K. Y., P. J. Yazaki, and H. van den Bosch. 1982. Purification of lysosomal phospholipase A. Evidence for multiple isoenzymes in rat liver. *J. Biol. Chem.* **257**: 13367–13373.
66. Hiraoka, M., A. Abe, and J. A. Shayman. 2002. Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. *J. Biol. Chem.* **277**: 10090–10099.
67. Umezū-Goto, M., Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G. B. Mills, K. Inoue, J. Aoki, et al. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. *J. Cell Biol.* **158**: 227–233.
68. Clair, T., J. Aoki, E. Koh, R. W. Bandle, S. W. Nam, M. M. Ptaszynska, G. B. Mills, E. Schiffmann, L. A. Liotta, and M. L. Stracke. 2003. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. *Cancer Res.* **63**: 5446–5453.
69. Van Meeteren, L. A., P. Ruurs, C. Stortelers, P. Bouwman, M. A. van Rooijen, J. P. Pradere, T. R. Pettit, M. J. Wakelam, J. S. Saulnier-Blache, C. L. Mummery, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. *Mol. Cell. Biol.* **26**: 5015–5022.